文献类型：期刊文献

英文题名：Norcantharidin analogues: a patent review (2006-2010)

作者：Deng, Liping[1];Tang, Shenlong[1]

机构：[1]Shaoxing Univ, Sch Chem & Chem Engn, Shaoxing 312000, Zhejiang, Peoples R China

年份：2011

卷号：21

期号：11

起止页码：1743

外文期刊名：EXPERT OPINION ON THERAPEUTIC PATENTS

收录：SCI-EXPANDED(收录号：WOS:000296091800004)、、Scopus(收录号：2-s2.0-80054922141)、WOS

基金：This paper was funded by a 10,000 Scientific Research Fund grant (Y2100872). The authors declare no other conflicts of interest.

语种：英文

外文关键词：anti-tumor; inhibitors; norcantharidin; norcantharimide; PP1; PP2A; PP5

外文摘要：Introduction: Norcantharidin (7-oxabicyclo [2.2.1] heptane-2,3-dicarboxylic anhydride) is the demethylated form of cantharidin. Norcantharidin not only has strong anticancer activity, but also eliminates most side-effects in the urinary system, does not cause myelosuppression and increases the number of white blood cells. With structural modification, norcantharidin analogues show potential anticancer activities. Areas covered: A comprehensive patent review of norcantharidin analogues from 2006 to 2010 is presented. Protein phosphatase 1, 2A, 2B and 5 inhibitors are described. The review summarizes the new compounds and lays the foundation for seeking more effective anticancer compounds. Expert opinion: Although norcantharidin has improved activity and toxicity, the effects routinely do not satisfy the current clinical need. Exploring better analogues is vital for changing the current situation, but norcantharidin is a good lead compound.